Advances in the Detection and Monitoring of Atrial Fibrillation for Patients with Cryptogenic Ischemic Stroke

Rajbeer Singh Sangha; Richard Bernstein

doi:10.1007/s11883-015-0544-3

Advances in the Detection and Monitoring of Atrial Fibrillation for Patients with Cryptogenic Ischemic Stroke

Rajbeer Singh Sangha^*, Richard Bernstein

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Atrial fibrillation (AF) is a significant etiologic cause of acute ischemic stroke (AIS) that leads to disabling deficits as well as significant morbidity and mortality in this population. Approximately 25 % of AIS is considered to be cryptogenic with no etiology ascertained at the time of the index event. Recent advances from the EMBRACE and CRYSTAL-AF trial have improved detection and treatment of AF and subsequently lead to changes in guidelines. However, with improved detection rates, the duration and frequency cutoffs for treating AF are currently being investigated to ensure optimization of patient selection and subsequent treatment.

Original language	English (US)
Article number	71
Journal	Current atherosclerosis reports
Volume	17
Issue number	12
DOIs	https://doi.org/10.1007/s11883-015-0544-3
State	Published - Dec 1 2015

Keywords

Acute ischemic stroke
Anticoagulation
Atrial arrhythmia
Atrial fibrillation
Holter monitor

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11883-015-0544-3

Cite this

@article{ccefa21434dd46e69518fef3f31542a6,

title = "Advances in the Detection and Monitoring of Atrial Fibrillation for Patients with Cryptogenic Ischemic Stroke",

abstract = "Atrial fibrillation (AF) is a significant etiologic cause of acute ischemic stroke (AIS) that leads to disabling deficits as well as significant morbidity and mortality in this population. Approximately 25 % of AIS is considered to be cryptogenic with no etiology ascertained at the time of the index event. Recent advances from the EMBRACE and CRYSTAL-AF trial have improved detection and treatment of AF and subsequently lead to changes in guidelines. However, with improved detection rates, the duration and frequency cutoffs for treating AF are currently being investigated to ensure optimization of patient selection and subsequent treatment.",

keywords = "Acute ischemic stroke, Anticoagulation, Atrial arrhythmia, Atrial fibrillation, Holter monitor",

author = "Sangha, {Rajbeer Singh} and Richard Bernstein",

note = "Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media New York.",

year = "2015",

month = dec,

day = "1",

doi = "10.1007/s11883-015-0544-3",

language = "English (US)",

volume = "17",

journal = "Current atherosclerosis reports",

issn = "1523-3804",

publisher = "Current Medicine Group",

number = "12",

}

TY - JOUR

T1 - Advances in the Detection and Monitoring of Atrial Fibrillation for Patients with Cryptogenic Ischemic Stroke

AU - Sangha, Rajbeer Singh

AU - Bernstein, Richard

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Atrial fibrillation (AF) is a significant etiologic cause of acute ischemic stroke (AIS) that leads to disabling deficits as well as significant morbidity and mortality in this population. Approximately 25 % of AIS is considered to be cryptogenic with no etiology ascertained at the time of the index event. Recent advances from the EMBRACE and CRYSTAL-AF trial have improved detection and treatment of AF and subsequently lead to changes in guidelines. However, with improved detection rates, the duration and frequency cutoffs for treating AF are currently being investigated to ensure optimization of patient selection and subsequent treatment.

AB - Atrial fibrillation (AF) is a significant etiologic cause of acute ischemic stroke (AIS) that leads to disabling deficits as well as significant morbidity and mortality in this population. Approximately 25 % of AIS is considered to be cryptogenic with no etiology ascertained at the time of the index event. Recent advances from the EMBRACE and CRYSTAL-AF trial have improved detection and treatment of AF and subsequently lead to changes in guidelines. However, with improved detection rates, the duration and frequency cutoffs for treating AF are currently being investigated to ensure optimization of patient selection and subsequent treatment.

KW - Acute ischemic stroke

KW - Anticoagulation

KW - Atrial arrhythmia

KW - Atrial fibrillation

KW - Holter monitor

UR - http://www.scopus.com/inward/record.url?scp=84944747699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944747699&partnerID=8YFLogxK

U2 - 10.1007/s11883-015-0544-3

DO - 10.1007/s11883-015-0544-3

M3 - Review article

C2 - 26490080

AN - SCOPUS:84944747699

SN - 1523-3804

VL - 17

JO - Current atherosclerosis reports

JF - Current atherosclerosis reports

IS - 12

M1 - 71

ER -

Advances in the Detection and Monitoring of Atrial Fibrillation for Patients with Cryptogenic Ischemic Stroke

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this